Making a Difference for Patients

We at Adamis Pharmaceuticals share a common goal of applying compassion and innovation to improve the lives of patients.

Company Overview
Commercial Products

Have a Question for Us?

Contact Us

Adamis Pharmaceuticals is a clinical stage neuro-biotechnology company focused on the development and commercialization of potential blockbuster products for the treatment of a variety of neuro-based disorders with significant unmet medical needs.

Linkedin Twitter

COMPANY

PRODUCTS

PIPELINE

INVESTORS & MEDIA

CONNECT

Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit https://dmkpharma.com/

Check this page for the most recent updates regarding the merger process.